CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response

Abstract CDK4/6 inhibitors are standard of care in the treatment of metastatic breast cancer. Treatment regimen consists of a combination with endocrine therapy, since their therapeutic efficacy as monotherapy in most clinical trials was rather limited. Thus, understanding the molecular mechanisms t...

Full description

Bibliographic Details

Published in:	Cell Death Discovery
Main Authors:	Ting Hong, Anna C. Hogger, Dongbiao Wang, Qi Pan, Julie Gansel, Thomas Engleitner, Rupert Öllinger, Jürgen E. Gschwend, Roland Rad, Roman Nawroth
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-10-01
Online Access:	https://doi.org/10.1038/s41420-024-02218-6